Juno’s lasting legacy: How the cell therapy juggernaut influenced biotech in Seattle and beyond When Juno Therapeutics launched in 2013, cell therapy was a nascent field. Early clinical studies were showing dramatic rates of… Read More
Seattle biotech vet Justine Dell’Aringa sees parallels in science while building her own home At home and at work, Justine Dell’Aringa is up for a challenge. The scientific associate director of Translational Research for… Read More
Fred Hutch names Thomas Lynch new president: ‘We’re going to make remarkable leaps’ Seattle’s Fred Hutchinson Cancer Research Center has found its next leader, announcing Tuesday that Dr. Thomas J. Lynch Jr. will… Read More
Bristol-Myers deal to acquire Juno parent Celgene delayed amid FTC concerns The $74 billion merger of Bristol-Myers Squibb and Celgene has been delayed as FTC pushback spurred Celgene to divest a… Read More
Bristol-Myers Squibb exec on how can Seattle grow — and keep — big biotech companies Henrik Andersen, head of biologics development at Bristol-Myers Squibb, knows what it’s like to be at a hot biotech when… Read More
Bristol-Myers Squibb’s $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert Things are a little on edge in Seattle’s biotech scene after the Jan. 3 announcement that pharmaceutical giant Bristol-Myers Squibb… Read More
